Human COQ4 deficiency: delineating the clinical, metabolic and neuroimaging phenotypes.

Laugwitz, Lucia; Seibt, Annette; Herebian, Diran; Peralta, Susana; Kienzle, Imke; Buchert, Rebecca; Falb, Ruth; Gauck, Darja et al. · J Med Genet · 2022

case_series · Level IV

Where this comes from

Abstract

Human coenzyme Q4 (COQ4) is essential for coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) biosynthesis. Pathogenic variants in <i>COQ4</i> cause childhood-onset neurodegeneration. We aimed to delineate the clinical spectrum and the cellular consequences of COQ4 deficiency. Clinical course and neuroradiological findings in a large cohort of paediatric patients with COQ4 deficiency were analysed. Functional studies in patient-derived cell lines were performed. We characterised 44 individuals from 36 families with COQ4 deficiency (16 newly described). A total of 23 different variants were identified, including four novel variants in <i>COQ4</i>. Correlation analyses of clinical and neuroimaging findings revealed three disease patterns: type 1: early-onset phenotype with neonatal brain anomalies and epileptic encephalopathy; type 2: intermediate phenotype with distinct stroke-like lesions; and type 3: moderate phenotype with non-specific brain pathology and a stable disease course. The functional relevance of <i>COQ4</i> variants was supported by in vitro studies using patient-derived fibroblast lines. Experiments revealed significantly decreased COQ4 protein levels, reduced levels of cellular CoQ<sub>10</sub> and elevated levels of the metabolic intermediate 6-demethoxyubiquinone. Our study describes the heterogeneous clinical presentation of COQ4 deficiency and identifies phenotypic subtypes. Cell-based studies support the pathogenic characteristics of <i>COQ4</i> variants. Due to the insufficient clinical response to oral CoQ<sub>10</sub> supplementation, alternative treatment strategies are warranted.

Medical subject headings